| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 51.4K | 1.9% | 1.4% |
| Total Income | 51.4K | 1.9% | 1.4% |
| Expenditure | 50.2K | 3.0% | 1.5% |
| PBT | 1.8K | 7.4% | 27.6% |
| Net Profit | 1.4K | 6.7% | 14.8% |
| OPM | 2.47% | 1.03pp | 0.09pp |
| NPM | 2.65% | 0.25pp | 0.31pp |
| EPS | 6.30 | 6.5% | 18.4% |
Elevance Health Reports Q3 2026 Results and Raises Full-Year Guidance
21 Oct 2026 · 21 Oct, 3:37 pm
Summary
Elevance Health reported third quarter 2026 results ahead of expectations, with operating revenue reaching $50.4 billion, a 0.7% increase year-over-year. The company raised its full-year 2026 guidance for both diluted EPS to at least $22.00 and adjusted diluted EPS to at least $29.00, driven by continued operating momentum. Management highlighted stronger execution across its diversified portfolio and expressed confidence in delivering at least 12% growth in adjusted diluted earnings per share in 2027.
Key Highlights
- 1
Elevance Health reported third quarter 2026 operating revenue of $50.4 billion, an increase of 0.7% from the prior year quarter.
- 2
The company reported third quarter 2026 diluted EPS of $6.27 and adjusted diluted EPS of $6.99.
- 3
Full-year 2026 diluted EPS guidance was raised to at least $22.00, and adjusted diluted EPS guidance was raised to at least $29.00.
- 4
Full-year 2026 operating cash flow guidance was raised to at least $6.5 billion.
- 5
Health Benefits segment operating revenue increased by 3% to $43.4 billion in the third quarter of 2026.
- 6
Carelon segment operating revenue increased by 5% to $19.3 billion in the third quarter of 2026.
- 7
The benefit expense ratio improved by 70 basis points to 90.6 percent in the third quarter of 2026.
Management Comments
Gail K. Boudreaux
Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business. We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.753. By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value for our shareholders.
Informational and educational content only. Not investment advice.